Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company has announced that the FDA has approved the use of Reyataz 300mg once-daily boosted with ritonavir 100mg as part of combination therapy in previously untreated HIV-1 infected patients.
Subscribe to our email newsletter
This use of once-daily Reyataz boosted with ritonavir (Reyataz/r) in HIV-1 infected treatment-naive adult patients is based on 48-week results from the Castle study, which demonstrated similar antiviral efficacy of Reyataz/r to twice-daily lopinavir/ritonavir, each as part of HIV combination therapy, in treatment-naive HIV-1 infected adult patients.
Reyataz/r taken once daily with food is recognized by the US Department of Health and Human Services (DHHS) as a preferred component of combination HIV therapy for treatment-naive patients. For treatment-naive patients who are unable to tolerate ritonavir, Reyataz 400mg (without ritonavir), taken once daily with food, is recommended.
Elliott Sigal, executive vice president, chief scientific officer and president of R&D at Bristol-Myers Squibb, said: “Bristol-Myers Squibb is committed to developing medicines that enhance the care of people living with HIV and AIDS. Boosted Reyataz provides healthcare professionals a newly approved, once-daily dosing option as part of combination therapy for patients naive to HIV therapy.”